董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jennifer S. Buell | 女 | Director | 51 | 741.52万美元 | 未持股 | 2026-01-08 |
| Susan Hirsch | 女 | Director | 73 | 22.00万美元 | 未持股 | 2026-01-08 |
| Garo H. Armen | 男 | Chairman and Chief Executive Officer and Interim Chief Financial Officer | 74 | 562.63万美元 | 未持股 | 2026-01-08 |
| Brian Corvese | 男 | Director | 69 | 58.95万美元 | 未持股 | 2026-01-08 |
| Timothy R. Wright | 男 | Director | 69 | 36.75万美元 | 未持股 | 2026-01-08 |
| Thomas Harrison | 男 | Director | 78 | 未披露 | 未持股 | 2026-01-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven O'Day | 男 | Chief Medical Officer | 64 | 131.12万美元 | 未持股 | 2026-01-08 |
| Austin Charette | 男 | Principal Accounting Officer | 37 | 未披露 | 未持股 | 2026-01-08 |
| Garo H. Armen | 男 | Chairman and Chief Executive Officer and Interim Chief Financial Officer | 74 | 562.63万美元 | 未持股 | 2026-01-08 |
| Christine M. Klaskin | 女 | Vice President of Finance | 60 | 62.81万美元 | 未持股 | 2026-01-08 |
董事简历
中英对照 | 中文 | 英文- Jennifer S. Buell
-
Jennifer S.Buell自2018年以来一直担任我们的首席运营官，并于2019年12月成为我们的总裁。2013年11月至2016年7月，Buell博士担任该公司的Vice President、研究与开发运营和项目管理。2016年7月至2017年11月，她担任公司Vice President、研究和对外事务，2017年11月至2018年11月，她担任首席通信和对外事务官。Buell博士在塔夫茨大学（Tufts University）获得细胞、生化和分子生物化学博士学位，并获得生物统计学硕士学位。
Jennifer S. Buell,has been President and CEO of MiNK Therapeutics, Inc. (subsidiary of Agenus) and since 2023 the Chairman, Executive Council at Agenus. From 2018 to 2021, Dr. Buell was President and Chief Operating Officer at Agenus, where she was responsible for organizational operations, investor relations and external affairs. Prior to Agenus, Dr. Buell held leadership positions in R&D operations at Bristol-Myers Squibb and Harvard Clinical Research Institute (Baim), where she was involved in the development strategy and operations for a portfolio of industry and government-sponsored clinical programs. She obtained her Ph.D. in Cellular, Biochemical, and Molecular Biochemistry with an M.S. in Biostatistics from Tufts University. - Jennifer S.Buell自2018年以来一直担任我们的首席运营官，并于2019年12月成为我们的总裁。2013年11月至2016年7月，Buell博士担任该公司的Vice President、研究与开发运营和项目管理。2016年7月至2017年11月，她担任公司Vice President、研究和对外事务，2017年11月至2018年11月，她担任首席通信和对外事务官。Buell博士在塔夫茨大学（Tufts University）获得细胞、生化和分子生物化学博士学位，并获得生物统计学硕士学位。
- Jennifer S. Buell,has been President and CEO of MiNK Therapeutics, Inc. (subsidiary of Agenus) and since 2023 the Chairman, Executive Council at Agenus. From 2018 to 2021, Dr. Buell was President and Chief Operating Officer at Agenus, where she was responsible for organizational operations, investor relations and external affairs. Prior to Agenus, Dr. Buell held leadership positions in R&D operations at Bristol-Myers Squibb and Harvard Clinical Research Institute (Baim), where she was involved in the development strategy and operations for a portfolio of industry and government-sponsored clinical programs. She obtained her Ph.D. in Cellular, Biochemical, and Molecular Biochemistry with an M.S. in Biostatistics from Tufts University.
- Susan Hirsch
-
Susan Hirsch，在投资管理和金融领域拥有超过40年的经验。Unit 2021年2月，她在TIAA公司Nuveen担任董事总经理和投资组合经理，负责管理超过200亿美元的资产，包括拥有66亿美元资产的TIAA-CREF大盘成长基金。在2005年加入Nuveen之前，她曾以Jennison Associates的身份担任中型增长和技术部门投资组合的执行副总裁兼投资组合经理。赫什女士之前的经历还包括在雷曼兄弟全球资产管理公司和德尔福资产管理公司担任精选成长股投资组合高级投资组合经理的投资管理职位。她的职业生涯始于美邦和雷曼兄弟的分析师，在那里，她的量化模型的成功使她随后在1991年、1992年和1993年被公认为小盘成长股的顶级机构分析师。Hirsch女士拥有布鲁克林学院的会计学学士学位。
Susan Hirsch,was a Managing Director and Portfolio Manager at Nuveen, a TIAA company, where she was responsible for managing over $20 billion in assets including the TIAA-CREF Large-Cap Growth Fund with $6.6 billion in assets. Prior to joining Nuveen in 2005, she served as Executive Vice President and Portfolio Manager for the Mid-Cap Growth and Technology Sector portfolios as Jennison Associates. Ms. Hirsch's previous experience also includes investment management positions at Lehman Brothers Global Asset Management and Delphi Asset Management as a Senior Portfolio Manager for the Selected Growth Stock Portfolio. She began her career as an analyst at Smith Barney and Lehman Brothers where the success of her quantitative model led to her subsequent recognition as a top ranked Institutional analyst for small cap growth stocks in 1991, 1992 and 1993. Ms. Hirsch holds a BS in Accounting from Brooklyn College. - Susan Hirsch，在投资管理和金融领域拥有超过40年的经验。Unit 2021年2月，她在TIAA公司Nuveen担任董事总经理和投资组合经理，负责管理超过200亿美元的资产，包括拥有66亿美元资产的TIAA-CREF大盘成长基金。在2005年加入Nuveen之前，她曾以Jennison Associates的身份担任中型增长和技术部门投资组合的执行副总裁兼投资组合经理。赫什女士之前的经历还包括在雷曼兄弟全球资产管理公司和德尔福资产管理公司担任精选成长股投资组合高级投资组合经理的投资管理职位。她的职业生涯始于美邦和雷曼兄弟的分析师，在那里，她的量化模型的成功使她随后在1991年、1992年和1993年被公认为小盘成长股的顶级机构分析师。Hirsch女士拥有布鲁克林学院的会计学学士学位。
- Susan Hirsch,was a Managing Director and Portfolio Manager at Nuveen, a TIAA company, where she was responsible for managing over $20 billion in assets including the TIAA-CREF Large-Cap Growth Fund with $6.6 billion in assets. Prior to joining Nuveen in 2005, she served as Executive Vice President and Portfolio Manager for the Mid-Cap Growth and Technology Sector portfolios as Jennison Associates. Ms. Hirsch's previous experience also includes investment management positions at Lehman Brothers Global Asset Management and Delphi Asset Management as a Senior Portfolio Manager for the Selected Growth Stock Portfolio. She began her career as an analyst at Smith Barney and Lehman Brothers where the success of her quantitative model led to her subsequent recognition as a top ranked Institutional analyst for small cap growth stocks in 1991, 1992 and 1993. Ms. Hirsch holds a BS in Accounting from Brooklyn College.
- Garo H. Armen
-
Garo H. Armen是Protagenic治疗公司的创始人之一，于2004年9月加入Protagenic治疗公司。Garo H. Armen是Agenus Inc.的董事长兼首席执行官，他在1994年与他人共同创立了一家生物技术公司。从2002年中到2004年，他还担任了成功重组的生物制药公司Elan Corporation，plc的董事会主席。在加入Agenus Inc.之前，Armen博士创立了Armen Partners，这是一家专门从事生物技术和制药公司业务的资金管理公司，并且是1993年创立Immunex Lederle肿瘤学公司这一广为人知的项目的设计者。在更早之前，他是Dean Witter Reynolds研究部高级副总裁，他的职业生涯始于华尔街，在EF Hutton担任分析师和投资银行家。2002年，Armen博士创立了亚美尼亚儿童基金会，这是一个非营利组织，致力于大力重建和振兴贫困的亚美尼亚农村城镇，为儿童和青年提供直接和可持续的利益。由于他的人道主义努力，他于2004年获得埃利斯岛荣誉勋章；由于他在生物技术和医学研究方面取得的成就，他于2006年获得萨宾疫苗研究所颁发的萨宾人道主义奖。Armen博士也是安永会计师事务所2002年纽约市年度生物技术企业家，并于2005年获得黑素瘤研究基金会颁发的希望之翼奖，以表彰他对黑素瘤社区的持续承诺。Armen博士在纽约城市大学研究生中心获得物理化学博士学位，之后他在纽约长岛的Brookhaven国家实验室担任研究员。
Garo H. Armen,oversaw the successful restructuring of the biopharmaceutical company Elan Corporation, plc, where he served as Chairman of the Board of Directors. Dr. Armen began his research career at Brookhaven National Laboratory subsequent to which he made a transition to Wall Street, as an analyst and investment banker at EF Hutton and then at Dean Witter Reynolds (now Morgan Stanley). Dr. Armen received his PhD in physical chemistry from the City University of New York. - Garo H. Armen是Protagenic治疗公司的创始人之一，于2004年9月加入Protagenic治疗公司。Garo H. Armen是Agenus Inc.的董事长兼首席执行官，他在1994年与他人共同创立了一家生物技术公司。从2002年中到2004年，他还担任了成功重组的生物制药公司Elan Corporation，plc的董事会主席。在加入Agenus Inc.之前，Armen博士创立了Armen Partners，这是一家专门从事生物技术和制药公司业务的资金管理公司，并且是1993年创立Immunex Lederle肿瘤学公司这一广为人知的项目的设计者。在更早之前，他是Dean Witter Reynolds研究部高级副总裁，他的职业生涯始于华尔街，在EF Hutton担任分析师和投资银行家。2002年，Armen博士创立了亚美尼亚儿童基金会，这是一个非营利组织，致力于大力重建和振兴贫困的亚美尼亚农村城镇，为儿童和青年提供直接和可持续的利益。由于他的人道主义努力，他于2004年获得埃利斯岛荣誉勋章；由于他在生物技术和医学研究方面取得的成就，他于2006年获得萨宾疫苗研究所颁发的萨宾人道主义奖。Armen博士也是安永会计师事务所2002年纽约市年度生物技术企业家，并于2005年获得黑素瘤研究基金会颁发的希望之翼奖，以表彰他对黑素瘤社区的持续承诺。Armen博士在纽约城市大学研究生中心获得物理化学博士学位，之后他在纽约长岛的Brookhaven国家实验室担任研究员。
- Garo H. Armen,oversaw the successful restructuring of the biopharmaceutical company Elan Corporation, plc, where he served as Chairman of the Board of Directors. Dr. Armen began his research career at Brookhaven National Laboratory subsequent to which he made a transition to Wall Street, as an analyst and investment banker at EF Hutton and then at Dean Witter Reynolds (now Morgan Stanley). Dr. Armen received his PhD in physical chemistry from the City University of New York.
- Brian Corvese
-
Brian Corvese，自1999年以来，他一直担任Vencor Capital（一家在中东和地中海地区进行电信和技术投资的私募股权公司）的总裁和创始人。在Vencor工作之前，他曾担任索罗斯基金管理公司（当时世界上最大的对冲基金）的董事总经理和合伙人，从事美国和全球股票市场的投资。从1988年到1996年，他是Chancellor Capital Management（一家250亿美元的资金管理公司）的合伙人。在Chancellor任职期间，他曾担任投资组合经理，负责基础行业、重组、特殊情况、公司治理投资的投资，以及创立和管理自己的对冲基金。从1981年到1988年，Corvese先生在Drexel Burnham Lambert（“Drexel”）担任股票分析师，跟踪化学和特种化学行业，并参与了大量的并购活动。在Drexel任职期间，他是机构投资者（Institutional Investor）排名的顶级化学和特种化学研究团队的成员。他目前担任MiNK Therapeutics， Inc.（位于埃及开罗的国家电信公司）和Protagenic Therapeutics （Agenus的子公司，位于加拿大安大略省）的董事会成员。他获得Rhode Island大学的金融和政治学学位，并就读于纽约大学研究生院。
Brian Corvese,worked on investments in the U.S. and global equity markets as a Managing Director and partner at Soros Fund Management, the largest hedge fund in the world at the time. From 1988 to 1996, Mr. Corvese was a partner at Chancellor Capital Management ("Chancellor"), a $25 billion money management firm. While at Chancellor, Mr. Corvese was a Portfolio Manager with responsibility for investments made in basic industries, restructurings, and special situations, corporate governance investments, as well as founded and managed his own hedge fund. From 1981 to 1988, Mr. Corvese was with Drexel Burnham Lambert ("Drexel") as an equity analyst following the chemical and specialty chemical industries and participated in a significant number of merger and acquisition activities. While at Drexel, Mr. Corvese was a member of the top chemical and specialty chemical research team, as ranked by Institutional Investor. Mr. Corvese currently serves on the Board of Directors of MiNK Therapeutics, Inc., the National Telecommunications Corporation, based in Cairo, Egypt, and Protagenic Therapeutics, an affiliate of Agenus, based in Ontario, Canada. Mr. Corvese earned degrees in finance and political science from The University of Rhode Island and attended New York University Graduate School. - Brian Corvese，自1999年以来，他一直担任Vencor Capital（一家在中东和地中海地区进行电信和技术投资的私募股权公司）的总裁和创始人。在Vencor工作之前，他曾担任索罗斯基金管理公司（当时世界上最大的对冲基金）的董事总经理和合伙人，从事美国和全球股票市场的投资。从1988年到1996年，他是Chancellor Capital Management（一家250亿美元的资金管理公司）的合伙人。在Chancellor任职期间，他曾担任投资组合经理，负责基础行业、重组、特殊情况、公司治理投资的投资，以及创立和管理自己的对冲基金。从1981年到1988年，Corvese先生在Drexel Burnham Lambert（“Drexel”）担任股票分析师，跟踪化学和特种化学行业，并参与了大量的并购活动。在Drexel任职期间，他是机构投资者（Institutional Investor）排名的顶级化学和特种化学研究团队的成员。他目前担任MiNK Therapeutics， Inc.（位于埃及开罗的国家电信公司）和Protagenic Therapeutics （Agenus的子公司，位于加拿大安大略省）的董事会成员。他获得Rhode Island大学的金融和政治学学位，并就读于纽约大学研究生院。
- Brian Corvese,worked on investments in the U.S. and global equity markets as a Managing Director and partner at Soros Fund Management, the largest hedge fund in the world at the time. From 1988 to 1996, Mr. Corvese was a partner at Chancellor Capital Management ("Chancellor"), a $25 billion money management firm. While at Chancellor, Mr. Corvese was a Portfolio Manager with responsibility for investments made in basic industries, restructurings, and special situations, corporate governance investments, as well as founded and managed his own hedge fund. From 1981 to 1988, Mr. Corvese was with Drexel Burnham Lambert ("Drexel") as an equity analyst following the chemical and specialty chemical industries and participated in a significant number of merger and acquisition activities. While at Drexel, Mr. Corvese was a member of the top chemical and specialty chemical research team, as ranked by Institutional Investor. Mr. Corvese currently serves on the Board of Directors of MiNK Therapeutics, Inc., the National Telecommunications Corporation, based in Cairo, Egypt, and Protagenic Therapeutics, an affiliate of Agenus, based in Ontario, Canada. Mr. Corvese earned degrees in finance and political science from The University of Rhode Island and attended New York University Graduate School.
- Timothy R. Wright
-
Timothy R. Wright，他自2019年4月以来一直担任Isosceles的执行主席。他还担任BIORG， INC 。的总裁兼首席执行官（2013年11月以来）。在担任这些职位之前，他是MiMedX（再生医学公司）的首席执行官。他目前还担任Agenus Inc.的董事会成员（2006年以来）。此外，他是the Ohio State University Comprehensive Cancer Center Drug Development Institute的创始人和前任主席。他还担任Washington University Medical School和North Carolina Veterinary School的顾问委员会成员。Wright先生曾在Covidien（现为Medtronic）、Teva Pharmaceuticals Industries Ltd.、DuPont Merck、Elan Bio-Pharmaceuticals、M2Gen Corp.担任多个行政职务。
Timothy R. Wright,is currently the President and CEO of BIORG, a human organoid company and a faculty member of Wake Forest Institute for Regenerative Medicine and has served in such role since November 2023. Mr. Wright is the former CEO of MiMedx Group, a placental biological company focused on regenerative medicine. Mr. Wright served as CEO and a member of the Board of Directors of MiMedx from May 2019 to September 2022. Mr. Wright has also served as a Founding Partner of Signal Hill Advisors, LLC since February 2011. Mr. Wright also served as chairman of The Ohio State University Comprehensive Cancer Center Drug Development Institute that he founded in 2011, and director of the Ohio State University Innovation Foundation until September 2022. Mr. Wright was the President and Chief Executive Officer and a director of M2Gen Corp., a privately held Cancer health informatics company, between July 2017 and September 2018. From April 2015 through July 2017, Mr. Wright was the Executive Vice President, Mergers and Acquisitions, Strategy and Innovation at Teva Pharmaceuticals Industries Ltd. Mr Wright has held several global executive roles throughout his career including President of Covidien Mallinkrodt, a medical imaging and pharmaceutical company (a subsidiary of Covidien, now Medtronic) from 2007-2010. Mr. Wright serves on the boards of Washington University Medical School and North Carolina State School of Veterinary Medicine. Mr. Wright earned his bachelor's degree from The Ohio State University. - Timothy R. Wright，他自2019年4月以来一直担任Isosceles的执行主席。他还担任BIORG， INC 。的总裁兼首席执行官（2013年11月以来）。在担任这些职位之前，他是MiMedX（再生医学公司）的首席执行官。他目前还担任Agenus Inc.的董事会成员（2006年以来）。此外，他是the Ohio State University Comprehensive Cancer Center Drug Development Institute的创始人和前任主席。他还担任Washington University Medical School和North Carolina Veterinary School的顾问委员会成员。Wright先生曾在Covidien（现为Medtronic）、Teva Pharmaceuticals Industries Ltd.、DuPont Merck、Elan Bio-Pharmaceuticals、M2Gen Corp.担任多个行政职务。
- Timothy R. Wright,is currently the President and CEO of BIORG, a human organoid company and a faculty member of Wake Forest Institute for Regenerative Medicine and has served in such role since November 2023. Mr. Wright is the former CEO of MiMedx Group, a placental biological company focused on regenerative medicine. Mr. Wright served as CEO and a member of the Board of Directors of MiMedx from May 2019 to September 2022. Mr. Wright has also served as a Founding Partner of Signal Hill Advisors, LLC since February 2011. Mr. Wright also served as chairman of The Ohio State University Comprehensive Cancer Center Drug Development Institute that he founded in 2011, and director of the Ohio State University Innovation Foundation until September 2022. Mr. Wright was the President and Chief Executive Officer and a director of M2Gen Corp., a privately held Cancer health informatics company, between July 2017 and September 2018. From April 2015 through July 2017, Mr. Wright was the Executive Vice President, Mergers and Acquisitions, Strategy and Innovation at Teva Pharmaceuticals Industries Ltd. Mr Wright has held several global executive roles throughout his career including President of Covidien Mallinkrodt, a medical imaging and pharmaceutical company (a subsidiary of Covidien, now Medtronic) from 2007-2010. Mr. Wright serves on the boards of Washington University Medical School and North Carolina State School of Veterinary Medicine. Mr. Wright earned his bachelor's degree from The Ohio State University.
- Thomas Harrison
-
Thomas Harrison, LH.D.，自2012年11月，在本公司担任董事。自1992年，他在Omnicom Group公司任职。目前，他在Diversified Agency Services担任荣誉主席。Diversified Agency Services是Omnicom Group公司的一个部门。在进入Omnicom Group公司之前，他是Harrison & Star Group公司的创始人和董事会主席。于1992年，他收购了Omnicom Group公司。Harrison & Star Group公司是一家医疗广告代理机构。他于1974年开始他的职业生涯，在Pfizer公司担任制药销售代表。随后，他建立并管理了多家医疗广告代理机构。目前，他在位于纽约的蒙蒂菲奥里医院（Montefiore Hospital）担任执行委员会成员，他还是纽约医学会（New York Academy of Medicine）的成员之一。他在Morgans Hotel Group公司担任董事，并在纽约医学会（New York Academy of Medicine）担任董事。此前，他在ePocrates公司和New York Chapter of the Arthritis Foundation公司担任董事。ePocrates公司是一家医疗信息公司。他于1972年在西弗吉尼亚大学（West Virginia University）获得了生物学和生理学学士学位，并于2007年获得荣誉博士的称号。
Thomas Harrison since June 2016,has served as Chairman Emeritus of the Diversified Agency Services "DAS" division of Omnicom Group Inc. (NYSE:OMC), the world's largest group of marketing services companies, having previously served as its President, then Chairman and CEO. DAS provides an unparalleled range of marketing communications services including public relations, crisis management, branding, sales promotion, customer relationship management and specialty communications including health care advertising. With over 5000 worldwide clients, the DAS division under Mr. Harrison had annual revenues of over $6.0 billion and became the largest business unit within Omnicom Group.Under Mr. Harrison's leadership, the DAS division grew from Omnicom's smallest to its largest division and accounted for over 50 of Omnicom's total revenues. He acquired and led a group of companies which became the most influential in their respective disciplines and built the largest, most innovative, diverse and relevant group of specialized agencies.Mr. Harrison's multi-faceted career brought him to Omnicom in 1992 when Omnicom acquired the firm he co-founded, Harrison & Star Business Group, which was the most successful and rapidly growing agency group in the healthcare industry. Mr. Harrison served as Chairman of the Harrison & Star Group and Chairman of Diversified Healthcare Communications, a group of eight healthcare agencies within Omnicom, until his appointment as President of DAS in 1997. He was named Chairman and Chief Executive of DAS in 1998 and remained in this role until being named Chairman Emeritus in 2013.With an advanced degree in cell biology and physiology, Mr. Harrison began his business career at Pfizer Laboratories as a pharmaceutical sales representative His agency, Harrison & Star, was an entrepreneurial agency that fused high science with high creativity. The agency became uniquely positioned in the market due to its understanding of the clinical and scientific underpinnings of prescription product promotion and its ability to communicate with practicing physicians using the language of science not sales.Mr. Harrison is a member of the Executive Committee of the Montefiore Health System and currently sits on the board of Fifth Street Asset Management (2014 - Present) where he serves as Lead Independent Director and Chairman of the Audit Committee. He also serves on the board of Madison Logic, a digital business to business agency (2017 - Present). Most recently, Mr. Harrison was appointed to the board of MainStem, a cannabis-related supply company and also ACTV8me, a digital advertising attribution company.Mr. Harrison is a past board member at ePocrates, a publicly traded healthcare information company, where he served from 2006 until its acquisition in 2013 and he has also served as a board member for The Morgans Hotel Group (2006 - 2013). Mr. Harrison joined the board of Dipexium Pharmaceuticals in 2011 and served until its acquisition in 2017. He was a board member of rVue, a digital out-of-home media company from 2013 until 2016 and sat on the board of Social Growth Technologies from 2014 until its acquisition in 2016. Mr. Harrison was appointed to the board of directors of Zynerba Pharmaceuticals in 2015 serving as Chair of the Nominations and Corporate Governance Committee and as a member of the Compensation Committee until 2019 when he joined Merida Capital Partners.Mr. Harrison earned an LH.D and Masters of Science in cell biology from West Virginia University, and a Bachelor of Science in cell biology and physiology from Shepherdstown University. - Thomas Harrison, LH.D.，自2012年11月，在本公司担任董事。自1992年，他在Omnicom Group公司任职。目前，他在Diversified Agency Services担任荣誉主席。Diversified Agency Services是Omnicom Group公司的一个部门。在进入Omnicom Group公司之前，他是Harrison & Star Group公司的创始人和董事会主席。于1992年，他收购了Omnicom Group公司。Harrison & Star Group公司是一家医疗广告代理机构。他于1974年开始他的职业生涯，在Pfizer公司担任制药销售代表。随后，他建立并管理了多家医疗广告代理机构。目前，他在位于纽约的蒙蒂菲奥里医院（Montefiore Hospital）担任执行委员会成员，他还是纽约医学会（New York Academy of Medicine）的成员之一。他在Morgans Hotel Group公司担任董事，并在纽约医学会（New York Academy of Medicine）担任董事。此前，他在ePocrates公司和New York Chapter of the Arthritis Foundation公司担任董事。ePocrates公司是一家医疗信息公司。他于1972年在西弗吉尼亚大学（West Virginia University）获得了生物学和生理学学士学位，并于2007年获得荣誉博士的称号。
- Thomas Harrison since June 2016,has served as Chairman Emeritus of the Diversified Agency Services "DAS" division of Omnicom Group Inc. (NYSE:OMC), the world's largest group of marketing services companies, having previously served as its President, then Chairman and CEO. DAS provides an unparalleled range of marketing communications services including public relations, crisis management, branding, sales promotion, customer relationship management and specialty communications including health care advertising. With over 5000 worldwide clients, the DAS division under Mr. Harrison had annual revenues of over $6.0 billion and became the largest business unit within Omnicom Group.Under Mr. Harrison's leadership, the DAS division grew from Omnicom's smallest to its largest division and accounted for over 50 of Omnicom's total revenues. He acquired and led a group of companies which became the most influential in their respective disciplines and built the largest, most innovative, diverse and relevant group of specialized agencies.Mr. Harrison's multi-faceted career brought him to Omnicom in 1992 when Omnicom acquired the firm he co-founded, Harrison & Star Business Group, which was the most successful and rapidly growing agency group in the healthcare industry. Mr. Harrison served as Chairman of the Harrison & Star Group and Chairman of Diversified Healthcare Communications, a group of eight healthcare agencies within Omnicom, until his appointment as President of DAS in 1997. He was named Chairman and Chief Executive of DAS in 1998 and remained in this role until being named Chairman Emeritus in 2013.With an advanced degree in cell biology and physiology, Mr. Harrison began his business career at Pfizer Laboratories as a pharmaceutical sales representative His agency, Harrison & Star, was an entrepreneurial agency that fused high science with high creativity. The agency became uniquely positioned in the market due to its understanding of the clinical and scientific underpinnings of prescription product promotion and its ability to communicate with practicing physicians using the language of science not sales.Mr. Harrison is a member of the Executive Committee of the Montefiore Health System and currently sits on the board of Fifth Street Asset Management (2014 - Present) where he serves as Lead Independent Director and Chairman of the Audit Committee. He also serves on the board of Madison Logic, a digital business to business agency (2017 - Present). Most recently, Mr. Harrison was appointed to the board of MainStem, a cannabis-related supply company and also ACTV8me, a digital advertising attribution company.Mr. Harrison is a past board member at ePocrates, a publicly traded healthcare information company, where he served from 2006 until its acquisition in 2013 and he has also served as a board member for The Morgans Hotel Group (2006 - 2013). Mr. Harrison joined the board of Dipexium Pharmaceuticals in 2011 and served until its acquisition in 2017. He was a board member of rVue, a digital out-of-home media company from 2013 until 2016 and sat on the board of Social Growth Technologies from 2014 until its acquisition in 2016. Mr. Harrison was appointed to the board of directors of Zynerba Pharmaceuticals in 2015 serving as Chair of the Nominations and Corporate Governance Committee and as a member of the Compensation Committee until 2019 when he joined Merida Capital Partners.Mr. Harrison earned an LH.D and Masters of Science in cell biology from West Virginia University, and a Bachelor of Science in cell biology and physiology from Shepherdstown University.
高管简历
中英对照 | 中文 | 英文- Steven O'Day
Steven O'Day，自2021年1月起担任Agenus Inc.首席医疗官。Dr. O'Day是CTLA-4抑制的先驱，在200多项临床试验中担任主要研究者。2015年至加入Agenus，担任普罗维登斯圣约翰健康中心John Wayne癌症研究所免疫-Onoclogy主任和临床研究主任。O'Day博士于1988年获得约翰霍普金斯医学院的医学博士学位，并于1983年获得威廉姆斯学院的化学学士学位。此外，O'Day博士还在达纳 Farber/哈佛癌症中心完成了他的医学肿瘤学研究金。
Steven O'Day,is a pioneer in CTLA-4 inhibition, and has been the principal investigator in more than 200 clinical trials. From 2015 until joining Agenus, was Director of Immuno-Oncology and Director of Clinical Research at John Wayne Cancer Institute at Providence Saint John's Health Center. Dr. O'Day received his medical degree in 1988 from Johns Hopkins School of Medicine and his BA in Chemistry from Williams College in 1983. Additionally, Dr. O'Day did his medical oncology fellowship at the Dana Farber/Harvard Cancer Center.- Steven O'Day，自2021年1月起担任Agenus Inc.首席医疗官。Dr. O'Day是CTLA-4抑制的先驱，在200多项临床试验中担任主要研究者。2015年至加入Agenus，担任普罗维登斯圣约翰健康中心John Wayne癌症研究所免疫-Onoclogy主任和临床研究主任。O'Day博士于1988年获得约翰霍普金斯医学院的医学博士学位，并于1983年获得威廉姆斯学院的化学学士学位。此外，O'Day博士还在达纳 Farber/哈佛癌症中心完成了他的医学肿瘤学研究金。
- Steven O'Day,is a pioneer in CTLA-4 inhibition, and has been the principal investigator in more than 200 clinical trials. From 2015 until joining Agenus, was Director of Immuno-Oncology and Director of Clinical Research at John Wayne Cancer Institute at Providence Saint John's Health Center. Dr. O'Day received his medical degree in 1988 from Johns Hopkins School of Medicine and his BA in Chemistry from Williams College in 1983. Additionally, Dr. O'Day did his medical oncology fellowship at the Dana Farber/Harvard Cancer Center.
- Austin Charette
Austin Charette，在公司的财务报告和合规职能中担任多个职责。在加入Agenus之前，Charette先生曾于2013年9月至2017年8月在Deloitte & Touche LLP的审计和鉴证业务中担任越来越多的职责。Charette先生拥有Roger 威廉姆斯大学计算机信息系统理学学士学位，以及东北大学会计学理学硕士和工商管理硕士学位。
Austin Charette,served in multiple roles of increasing responsibility in the Company's financial reporting and compliance function. Prior to joining Agenus, Mr. Charette served in roles of increasing responsibility within the audit and assurance practice of Deloitte & Touche LLP from September 2013 to August 2017. Mr. Charette earned a Bachelor of Science in Computer Information Systems from Roger Williams University and both a Master of Science in Accounting and a Master of Business Administration from Northeastern University.- Austin Charette，在公司的财务报告和合规职能中担任多个职责。在加入Agenus之前，Charette先生曾于2013年9月至2017年8月在Deloitte & Touche LLP的审计和鉴证业务中担任越来越多的职责。Charette先生拥有Roger 威廉姆斯大学计算机信息系统理学学士学位，以及东北大学会计学理学硕士和工商管理硕士学位。
- Austin Charette,served in multiple roles of increasing responsibility in the Company's financial reporting and compliance function. Prior to joining Agenus, Mr. Charette served in roles of increasing responsibility within the audit and assurance practice of Deloitte & Touche LLP from September 2013 to August 2017. Mr. Charette earned a Bachelor of Science in Computer Information Systems from Roger Williams University and both a Master of Science in Accounting and a Master of Business Administration from Northeastern University.
- Garo H. Armen
Garo H. Armen是Protagenic治疗公司的创始人之一，于2004年9月加入Protagenic治疗公司。Garo H. Armen是Agenus Inc.的董事长兼首席执行官，他在1994年与他人共同创立了一家生物技术公司。从2002年中到2004年，他还担任了成功重组的生物制药公司Elan Corporation，plc的董事会主席。在加入Agenus Inc.之前，Armen博士创立了Armen Partners，这是一家专门从事生物技术和制药公司业务的资金管理公司，并且是1993年创立Immunex Lederle肿瘤学公司这一广为人知的项目的设计者。在更早之前，他是Dean Witter Reynolds研究部高级副总裁，他的职业生涯始于华尔街，在EF Hutton担任分析师和投资银行家。2002年，Armen博士创立了亚美尼亚儿童基金会，这是一个非营利组织，致力于大力重建和振兴贫困的亚美尼亚农村城镇，为儿童和青年提供直接和可持续的利益。由于他的人道主义努力，他于2004年获得埃利斯岛荣誉勋章；由于他在生物技术和医学研究方面取得的成就，他于2006年获得萨宾疫苗研究所颁发的萨宾人道主义奖。Armen博士也是安永会计师事务所2002年纽约市年度生物技术企业家，并于2005年获得黑素瘤研究基金会颁发的希望之翼奖，以表彰他对黑素瘤社区的持续承诺。Armen博士在纽约城市大学研究生中心获得物理化学博士学位，之后他在纽约长岛的Brookhaven国家实验室担任研究员。
Garo H. Armen,oversaw the successful restructuring of the biopharmaceutical company Elan Corporation, plc, where he served as Chairman of the Board of Directors. Dr. Armen began his research career at Brookhaven National Laboratory subsequent to which he made a transition to Wall Street, as an analyst and investment banker at EF Hutton and then at Dean Witter Reynolds (now Morgan Stanley). Dr. Armen received his PhD in physical chemistry from the City University of New York.- Garo H. Armen是Protagenic治疗公司的创始人之一，于2004年9月加入Protagenic治疗公司。Garo H. Armen是Agenus Inc.的董事长兼首席执行官，他在1994年与他人共同创立了一家生物技术公司。从2002年中到2004年，他还担任了成功重组的生物制药公司Elan Corporation，plc的董事会主席。在加入Agenus Inc.之前，Armen博士创立了Armen Partners，这是一家专门从事生物技术和制药公司业务的资金管理公司，并且是1993年创立Immunex Lederle肿瘤学公司这一广为人知的项目的设计者。在更早之前，他是Dean Witter Reynolds研究部高级副总裁，他的职业生涯始于华尔街，在EF Hutton担任分析师和投资银行家。2002年，Armen博士创立了亚美尼亚儿童基金会，这是一个非营利组织，致力于大力重建和振兴贫困的亚美尼亚农村城镇，为儿童和青年提供直接和可持续的利益。由于他的人道主义努力，他于2004年获得埃利斯岛荣誉勋章；由于他在生物技术和医学研究方面取得的成就，他于2006年获得萨宾疫苗研究所颁发的萨宾人道主义奖。Armen博士也是安永会计师事务所2002年纽约市年度生物技术企业家，并于2005年获得黑素瘤研究基金会颁发的希望之翼奖，以表彰他对黑素瘤社区的持续承诺。Armen博士在纽约城市大学研究生中心获得物理化学博士学位，之后他在纽约长岛的Brookhaven国家实验室担任研究员。
- Garo H. Armen,oversaw the successful restructuring of the biopharmaceutical company Elan Corporation, plc, where he served as Chairman of the Board of Directors. Dr. Armen began his research career at Brookhaven National Laboratory subsequent to which he made a transition to Wall Street, as an analyst and investment banker at EF Hutton and then at Dean Witter Reynolds (now Morgan Stanley). Dr. Armen received his PhD in physical chemistry from the City University of New York.
- Christine M. Klaskin
Christine M. Klaskin，自2012年起担任董事会的成员。自2006年以来，她是Agenus公司（纳斯达克交易代码：AGEN）的财务副总裁，一家开发和商业化技术来治疗癌症和传染性疾病的生物技术公司。克拉斯女士在1996年加入Agenus公司，并担任各种财务职位。从1987年到1996年，她任职于安达信会计师事务所，最近担任审计经理。克拉斯女士获得乔治华盛顿大学的会计学学士学位。
Christine M. Klaskin,has held various positions within the finance department and has been involved in all equity and debt offerings of the Company including its IPO. Additionally, Ms. Klaskin serves as the Treasurer of MiNK Therapeutics, Inc. Prior to joining Agenus, Ms. Klaskin was employed by Arthur Andersen as an audit manager. Ms. Klaskin received her Bachelor of Accountancy from The George Washington University.- Christine M. Klaskin，自2012年起担任董事会的成员。自2006年以来，她是Agenus公司（纳斯达克交易代码：AGEN）的财务副总裁，一家开发和商业化技术来治疗癌症和传染性疾病的生物技术公司。克拉斯女士在1996年加入Agenus公司，并担任各种财务职位。从1987年到1996年，她任职于安达信会计师事务所，最近担任审计经理。克拉斯女士获得乔治华盛顿大学的会计学学士学位。
- Christine M. Klaskin,has held various positions within the finance department and has been involved in all equity and debt offerings of the Company including its IPO. Additionally, Ms. Klaskin serves as the Treasurer of MiNK Therapeutics, Inc. Prior to joining Agenus, Ms. Klaskin was employed by Arthur Andersen as an audit manager. Ms. Klaskin received her Bachelor of Accountancy from The George Washington University.